Virological evaluation of treating HIV-infected patients with (combinations of) antiretroviral drugs at the Amsterdam Academic Medical Center, 1996/'97
OBJECTIVE: First clinical virological evaluation of anti-HIV treatment with HIV reverse transcriptase (RT) and protease inhibitors.
DESIGN: Descriptive.
SETTING: Academic Medical Centre of the University of Amsterdam, the Netherlands.
METHOD: From January 1, 1996, until May 1, 1997, HIV-RNA levels were determined in sequential serum or plasma samples obtained sequentially of 384 patients over a period of 3.1 years on average (minimum 0.5, maximum 10 years). Of these patients 318 had sustained treatment for at least 6 months. The effect on HIV-RNA serum or plasma levels was evaluated in this particular group, of which 224 (70.4%) had been pretreated with antiretroviral drugs (experienced patients) and 94 (29.6%) had not (naive patients).
RESULTS: Of the naive patients 8.5% were treated with a combination of two, 89.4% with three and 2.1% with four anti-HIV drugs. Preceding their current treatment, an average of more than two other anti-HIV regimens had been administered to the experienced patients. From 1987 until May 1997 a total of 834 treatments were registered among the 224 patients: 202 mono, 223 double, 340 triple, 60 quadruple and 9 other combination treatments. After six months 84% of the triple combination treatments in the naive patients and 61% in the experienced patients resulted in RNA levels < or = 10(3) copies/ml (p = 0.008). Of 68 patients who failed on treatment 36 (52.9%) showed resistance associated mutations in HIV reverse transcriptase. In 6/43 (14%) of these patients resistance associated mutations in protease were found as well. Genotypic resistance could not always be confirmed phenotypically.
CONCLUSION: Our preliminary results indicate that in a majority of cases triple combination treatment including at least one HIV protease inhibitor was successful. Nevertheless, in 16% of the therapy-naive and 39% of the therapy-experienced patients the anti-HIV effect of treatment was insufficient.
| Errataetall: |
CommentIn: Ned Tijdschr Geneeskd. 1998 May 16;142(20):1169-70. - PMID 9623246 |
|---|---|
| Medienart: |
Artikel |
| Erscheinungsjahr: |
1998 |
|---|---|
| Erschienen: |
1998 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:142 |
|---|---|
| Enthalten in: |
Nederlands tijdschrift voor geneeskunde - 142(1998), 11 vom: 14. März, Seite 573-8 |
| Sprache: |
Niederländisch |
|---|
| Weiterer Titel: |
Virologische evaluatie van behandeling van HIV-geïnfecteerden met (combinaties van) antiretrovirale middelen in het Academisch Medisch Centrum Amsterdam, 1996/'97 |
|---|
| Beteiligte Personen: |
de Wolf, F [VerfasserIn] |
|---|
| Themen: |
Antiviral Agents |
|---|
| Anmerkungen: |
Date Completed 16.07.1998 Date Revised 15.11.2006 published: Print CommentIn: Ned Tijdschr Geneeskd. 1998 May 16;142(20):1169-70. - PMID 9623246 Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM095632794 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM095632794 | ||
| 003 | DE-627 | ||
| 005 | 20231222102155.0 | ||
| 007 | tu | ||
| 008 | 231222s1998 xx ||||| 00| ||dut c | ||
| 028 | 5 | 2 | |a pubmed24n0319.xml |
| 035 | |a (DE-627)NLM095632794 | ||
| 035 | |a (NLM)9623114 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a dut | ||
| 100 | 1 | |a de Wolf, F |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Virological evaluation of treating HIV-infected patients with (combinations of) antiretroviral drugs at the Amsterdam Academic Medical Center, 1996/'97 |
| 246 | 3 | 3 | |a Virologische evaluatie van behandeling van HIV-geïnfecteerden met (combinaties van) antiretrovirale middelen in het Academisch Medisch Centrum Amsterdam, 1996/'97 |
| 264 | 1 | |c 1998 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 16.07.1998 | ||
| 500 | |a Date Revised 15.11.2006 | ||
| 500 | |a published: Print | ||
| 500 | |a CommentIn: Ned Tijdschr Geneeskd. 1998 May 16;142(20):1169-70. - PMID 9623246 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a OBJECTIVE: First clinical virological evaluation of anti-HIV treatment with HIV reverse transcriptase (RT) and protease inhibitors | ||
| 520 | |a DESIGN: Descriptive | ||
| 520 | |a SETTING: Academic Medical Centre of the University of Amsterdam, the Netherlands | ||
| 520 | |a METHOD: From January 1, 1996, until May 1, 1997, HIV-RNA levels were determined in sequential serum or plasma samples obtained sequentially of 384 patients over a period of 3.1 years on average (minimum 0.5, maximum 10 years). Of these patients 318 had sustained treatment for at least 6 months. The effect on HIV-RNA serum or plasma levels was evaluated in this particular group, of which 224 (70.4%) had been pretreated with antiretroviral drugs (experienced patients) and 94 (29.6%) had not (naive patients) | ||
| 520 | |a RESULTS: Of the naive patients 8.5% were treated with a combination of two, 89.4% with three and 2.1% with four anti-HIV drugs. Preceding their current treatment, an average of more than two other anti-HIV regimens had been administered to the experienced patients. From 1987 until May 1997 a total of 834 treatments were registered among the 224 patients: 202 mono, 223 double, 340 triple, 60 quadruple and 9 other combination treatments. After six months 84% of the triple combination treatments in the naive patients and 61% in the experienced patients resulted in RNA levels < or = 10(3) copies/ml (p = 0.008). Of 68 patients who failed on treatment 36 (52.9%) showed resistance associated mutations in HIV reverse transcriptase. In 6/43 (14%) of these patients resistance associated mutations in protease were found as well. Genotypic resistance could not always be confirmed phenotypically | ||
| 520 | |a CONCLUSION: Our preliminary results indicate that in a majority of cases triple combination treatment including at least one HIV protease inhibitor was successful. Nevertheless, in 16% of the therapy-naive and 39% of the therapy-experienced patients the anti-HIV effect of treatment was insufficient | ||
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 650 | 7 | |a Protease Inhibitors |2 NLM | |
| 650 | 7 | |a RNA, Viral |2 NLM | |
| 650 | 7 | |a Reverse Transcriptase Inhibitors |2 NLM | |
| 700 | 1 | |a de Jong, J J |e verfasserin |4 aut | |
| 700 | 1 | |a Hertogs, K |e verfasserin |4 aut | |
| 700 | 1 | |a Danner, S A |e verfasserin |4 aut | |
| 700 | 1 | |a Lange, J M |e verfasserin |4 aut | |
| 700 | 1 | |a Goudsmit, J |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Nederlands tijdschrift voor geneeskunde |d 1946 |g 142(1998), 11 vom: 14. März, Seite 573-8 |w (DE-627)NLM000034231 |x 1876-8784 |7 nnns |
| 773 | 1 | 8 | |g volume:142 |g year:1998 |g number:11 |g day:14 |g month:03 |g pages:573-8 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 142 |j 1998 |e 11 |b 14 |c 03 |h 573-8 | ||